MovDisordV3, PascalFrancis, Curation, bibRecord, 002A33

Perampanel, an AMPA Antagonist, Found to Have No Benefit in Reducing "Off" Time in Parkinson's Disease

Identifieur interne : 002A33 ( PascalFrancis/Curation ); précédent : 002A32; suivant : 002A34

Perampanel, an AMPA Antagonist, Found to Have No Benefit in Reducing "Off" Time in Parkinson's Disease

Auteurs : Andrew Lees [Royaume-Uni] ; Stanley Fahn [États-Unis] ; Karla M. Eggert [Allemagne] ; Joseph Jankovic [États-Unis] ; Anthony Lang [Canada] ; Federico Micheli [Argentine] ; M. Maral Mouradian [États-Unis] ; Wolfgang H. Oertel [Allemagne] ; C. Warren Olanow [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Eduardo Tolosa [Espagne] ; David Squillacote [États-Unis] ; Dinesh Kumar [États-Unis]

Source :

Movement disorders [ 0885-3185 ] ; 2012.

RBID : Pascal:12-0113807

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Pathologie du système nerveux, Pérampanel, Récepteur AMPA, Fluctuation, Sécurité.

English descriptors

KwdEn :
- AMPA receptor, Fluctuations, Nervous system diseases, Parkinson disease, Perampanel, Safety.

Abstract

Background: Perampanel is a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor antagonist. Two multicenter randomized, double-blind, placebo-controlled, parallel-group phase III studies assessed the efficacy and safety of adjunctive perampanel in patients with Parkinson's disease and motor fluctuations. Methods: In both phase III studies (301 and 302), levodopa-treated patients were randomized and treated with once-daily oral placebo (n = 504), perampanel 2 mg (n = 509), or perampanel 4 mg (n = 501). The primary end point was change in daily "off" time from baseline. The treatment period was 30 weeks in study 301 and 20 weeks in study 302. Results: For any efficacy end point, perampanel 2 or 4 mg was not superior to placebo. Perampanel was well tolerated up to 4 mg/day. Conclusions: Perampanel failed to significantly improve motor symptoms versus placebo. There was also no effect on the duration or disability of levodopa-induced dyskinesia.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 27`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Perampanel, an AMPA Antagonist, Found to Have No Benefit in Reducing "Off" Time in Parkinson's Disease`
A11	`01`	`1`		`@1 LEES (Andrew)`
A11	`02`	`1`		`@1 FAHN (Stanley)`
A11	`03`	`1`		`@1 EGGERT (Karla M.)`
A11	`04`	`1`		`@1 JANKOVIC (Joseph)`
A11	`05`	`1`		`@1 LANG (Anthony)`
A11	`06`	`1`		`@1 MICHELI (Federico)`
A11	`07`	`1`		`@1 MARAL MOURADIAN (M.)`
A11	`08`	`1`		`@1 OERTEL (Wolfgang H.)`
A11	`09`	`1`		`@1 OLANOW (C. Warren)`
A11	`10`	`1`		`@1 POEWE (Werner)`
A11	`11`	`1`		`@1 RASCOL (Olivier)`
A11	`12`	`1`		`@1 TOLOSA (Eduardo)`
A11	`13`	`1`		`@1 SQUILLACOTE (David)`
A11	`14`	`1`		`@1 KUMAR (Dinesh)`
A14	`01`			`@1 Reta Lila Weston Institute for Neurological Studies, University College London @2 London @3 GBR @Z 1 aut.`
A14	`02`			`@1 Department of Neurology, Columbia University College of Physicians and Surgeons, New York @2 New York @3 USA @Z 2 aut.`
A14	`03`			`@1 Department of Neurology, Philipps University Marburg @2 Marburg @3 DEU @Z 3 aut. @Z 8 aut.`
A14	`04`			`@1 Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine @2 Houston, Texas @3 USA @Z 4 aut.`
A14	`05`			`@1 Toronto Western Hospital, University of Toronto @2 Toronto, Ontario @3 CAN @Z 5 aut.`
A14	`06`			`@1 Parkinson's Disease and Movement Disorders Program, Hospital de Clínicas, University of Buenos Aires @2 Buenos Aires @3 ARG @Z 6 aut.`
A14	`07`			`@1 Center for Neurodegenerative and Neuroimmunologic Diseases, Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School @2 Piscataway, New Jersey @3 USA @Z 7 aut.`
A14	`08`			`@1 Mount Sinai School of Medicine, New York @2 New York @3 USA @Z 9 aut.`
A14	`09`			`@1 Department of Neurology, Innsbruck Medical University @2 Innsbruck @3 AUT @Z 10 aut.`
A14	`10`			`@1 Departments of Clinical Pharmacology and Neurosciences, INSERM Clinical Investigation Center CIC9302, University of Toulouse III and University Hospital of Toulouse @2 Toulouse @3 FRA @Z 11 aut.`
A14	`11`			`@1 Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clinic, IDIBAPS, Universitat de Barcelona @2 Barcelona @3 ESP @Z 12 aut.`
A14	`12`			`@1 Eisai Neuroscience Product Creation Unit @2 Woodcliff Lake, New Jersey @3 USA @Z 13 aut. @Z 14 aut.`
A20				`@1 284-288`
A21				`@1 2012`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000508698420180`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 14 ref.`
A47	`01`	`1`		`@0 12-0113807`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Background: Perampanel is a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor antagonist. Two multicenter randomized, double-blind, placebo-controlled, parallel-group phase III studies assessed the efficacy and safety of adjunctive perampanel in patients with Parkinson's disease and motor fluctuations. Methods: In both phase III studies (301 and 302), levodopa-treated patients were randomized and treated with once-daily oral placebo (n = 504), perampanel 2 mg (n = 509), or perampanel 4 mg (n = 501). The primary end point was change in daily "off" time from baseline. The treatment period was 30 weeks in study 301 and 20 weeks in study 302. Results: For any efficacy end point, perampanel 2 or 4 mg was not superior to placebo. Perampanel was well tolerated up to 4 mg/day. Conclusions: Perampanel failed to significantly improve motor symptoms versus placebo. There was also no effect on the duration or disability of levodopa-induced dyskinesia.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 02`
C03	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 02`
C03	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Pérampanel @2 FR @5 09`
C03	`03`	`X`	`ENG`	`@0 Perampanel @2 FR @5 09`
C03	`03`	`X`	`SPA`	`@0 Perampanel @2 FR @5 09`
C03	`04`	`X`	`FRE`	`@0 Récepteur AMPA @5 10`
C03	`04`	`X`	`ENG`	`@0 AMPA receptor @5 10`
C03	`04`	`X`	`SPA`	`@0 Receptor AMPA @5 10`
C03	`05`	`X`	`FRE`	`@0 Fluctuation @5 11`
C03	`05`	`X`	`ENG`	`@0 Fluctuations @5 11`
C03	`05`	`X`	`SPA`	`@0 Fluctuación @5 11`
C03	`06`	`X`	`FRE`	`@0 Sécurité @5 12`
C03	`06`	`X`	`ENG`	`@0 Safety @5 12`
C03	`06`	`X`	`SPA`	`@0 Seguridad @5 12`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Récepteur glutamate @5 42`
C07	`05`	`X`	`ENG`	`@0 Glutamate receptor @5 42`
C07	`05`	`X`	`SPA`	`@0 Receptor glutámato @5 42`
N21				`@1 086`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000281

Links to Exploration step

Pascal:12-0113807

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Perampanel, an AMPA Antagonist, Found to Have No Benefit in Reducing "Off" Time in Parkinson's Disease</title>
<author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Reta Lila Weston Institute for Neurological Studies, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Columbia University College of Physicians and Surgeons, New York</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Eggert, Karla M" sort="Eggert, Karla M" uniqKey="Eggert K" first="Karla M." last="Eggert">Karla M. Eggert</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, Philipps University Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony" sort="Lang, Anthony" uniqKey="Lang A" first="Anthony" last="Lang">Anthony Lang</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Toronto Western Hospital, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Micheli, Federico" sort="Micheli, Federico" uniqKey="Micheli F" first="Federico" last="Micheli">Federico Micheli</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Parkinson's Disease and Movement Disorders Program, Hospital de Clínicas, University of Buenos Aires</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Argentine</country>
</affiliation>
</author>
<author><name sortKey="Maral Mouradian, M" sort="Maral Mouradian, M" uniqKey="Maral Mouradian M" first="M." last="Maral Mouradian">M. Maral Mouradian</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Center for Neurodegenerative and Neuroimmunologic Diseases, Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School</s1>
<s2>Piscataway, New Jersey</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, Philipps University Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Mount Sinai School of Medicine, New York</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Neurology, Innsbruck Medical University</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Departments of Clinical Pharmacology and Neurosciences, INSERM Clinical Investigation Center CIC9302, University of Toulouse III and University Hospital of Toulouse</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clinic, IDIBAPS, Universitat de Barcelona</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author><name sortKey="Squillacote, David" sort="Squillacote, David" uniqKey="Squillacote D" first="David" last="Squillacote">David Squillacote</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Eisai Neuroscience Product Creation Unit</s1>
<s2>Woodcliff Lake, New Jersey</s2>
<s3>USA</s3>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Kumar, Dinesh" sort="Kumar, Dinesh" uniqKey="Kumar D" first="Dinesh" last="Kumar">Dinesh Kumar</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Eisai Neuroscience Product Creation Unit</s1>
<s2>Woodcliff Lake, New Jersey</s2>
<s3>USA</s3>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0113807</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0113807 INIST</idno>
<idno type="RBID">Pascal:12-0113807</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000281</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002A33</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Perampanel, an AMPA Antagonist, Found to Have No Benefit in Reducing "Off" Time in Parkinson's Disease</title>
<author><name sortKey="Lees, Andrew" sort="Lees, Andrew" uniqKey="Lees A" first="Andrew" last="Lees">Andrew Lees</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Reta Lila Weston Institute for Neurological Studies, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Columbia University College of Physicians and Surgeons, New York</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Eggert, Karla M" sort="Eggert, Karla M" uniqKey="Eggert K" first="Karla M." last="Eggert">Karla M. Eggert</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, Philipps University Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony" sort="Lang, Anthony" uniqKey="Lang A" first="Anthony" last="Lang">Anthony Lang</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Toronto Western Hospital, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
</affiliation>
</author>
<author><name sortKey="Micheli, Federico" sort="Micheli, Federico" uniqKey="Micheli F" first="Federico" last="Micheli">Federico Micheli</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Parkinson's Disease and Movement Disorders Program, Hospital de Clínicas, University of Buenos Aires</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Argentine</country>
</affiliation>
</author>
<author><name sortKey="Maral Mouradian, M" sort="Maral Mouradian, M" uniqKey="Maral Mouradian M" first="M." last="Maral Mouradian">M. Maral Mouradian</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Center for Neurodegenerative and Neuroimmunologic Diseases, Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School</s1>
<s2>Piscataway, New Jersey</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Oertel, Wolfgang H" sort="Oertel, Wolfgang H" uniqKey="Oertel W" first="Wolfgang H." last="Oertel">Wolfgang H. Oertel</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, Philipps University Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
</affiliation>
</author>
<author><name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Mount Sinai School of Medicine, New York</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Department of Neurology, Innsbruck Medical University</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Departments of Clinical Pharmacology and Neurosciences, INSERM Clinical Investigation Center CIC9302, University of Toulouse III and University Hospital of Toulouse</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clinic, IDIBAPS, Universitat de Barcelona</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Espagne</country>
</affiliation>
</author>
<author><name sortKey="Squillacote, David" sort="Squillacote, David" uniqKey="Squillacote D" first="David" last="Squillacote">David Squillacote</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Eisai Neuroscience Product Creation Unit</s1>
<s2>Woodcliff Lake, New Jersey</s2>
<s3>USA</s3>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Kumar, Dinesh" sort="Kumar, Dinesh" uniqKey="Kumar D" first="Dinesh" last="Kumar">Dinesh Kumar</name>
<affiliation wicri:level="1"><inist:fA14 i1="12"><s1>Eisai Neuroscience Product Creation Unit</s1>
<s2>Woodcliff Lake, New Jersey</s2>
<s3>USA</s3>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AMPA receptor</term>
<term>Fluctuations</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Perampanel</term>
<term>Safety</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Pathologie du   système nerveux</term>
<term>Pérampanel</term>
<term>Récepteur AMPA</term>
<term>Fluctuation</term>
<term>Sécurité</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Perampanel is a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor antagonist. Two multicenter randomized, double-blind, placebo-controlled, parallel-group phase III studies assessed the efficacy and safety of adjunctive perampanel in patients with Parkinson's disease and motor fluctuations. Methods: In both phase III studies (301 and 302), levodopa-treated patients were randomized and treated with once-daily oral placebo (n = 504), perampanel 2 mg (n = 509), or perampanel 4 mg (n = 501). The primary end point was change in daily "off" time from baseline. The treatment period was 30 weeks in study 301 and 20 weeks in study 302. Results: For any efficacy end point, perampanel 2 or 4 mg was not superior to placebo. Perampanel was well tolerated up to 4 mg/day. Conclusions: Perampanel failed to significantly improve motor symptoms versus placebo. There was also no effect on the duration or disability of levodopa-induced dyskinesia.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>27</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Perampanel, an AMPA Antagonist, Found to Have No Benefit in Reducing "Off" Time in Parkinson's Disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>LEES (Andrew)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>FAHN (Stanley)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>EGGERT (Karla M.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>JANKOVIC (Joseph)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>LANG (Anthony)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MICHELI (Federico)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>MARAL MOURADIAN (M.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>OERTEL (Wolfgang H.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>OLANOW (C. Warren)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>POEWE (Werner)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>RASCOL (Olivier)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>TOLOSA (Eduardo)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>SQUILLACOTE (David)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>KUMAR (Dinesh)</s1>
</fA11>
<fA14 i1="01"><s1>Reta Lila Weston Institute for Neurological Studies, University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, Columbia University College of Physicians and Surgeons, New York</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology, Philipps University Marburg</s1>
<s2>Marburg</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Toronto Western Hospital, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Parkinson's Disease and Movement Disorders Program, Hospital de Clínicas, University of Buenos Aires</s1>
<s2>Buenos Aires</s2>
<s3>ARG</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Center for Neurodegenerative and Neuroimmunologic Diseases, Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School</s1>
<s2>Piscataway, New Jersey</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Mount Sinai School of Medicine, New York</s1>
<s2>New York</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Department of Neurology, Innsbruck Medical University</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Departments of Clinical Pharmacology and Neurosciences, INSERM Clinical Investigation Center CIC9302, University of Toulouse III and University Hospital of Toulouse</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>Neurology Service, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clinic, IDIBAPS, Universitat de Barcelona</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="12"><s1>Eisai Neuroscience Product Creation Unit</s1>
<s2>Woodcliff Lake, New Jersey</s2>
<s3>USA</s3>
<sZ>13 aut.</sZ>
<sZ>14 aut.</sZ>
</fA14>
<fA20><s1>284-288</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000508698420180</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>14 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0113807</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: Perampanel is a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor antagonist. Two multicenter randomized, double-blind, placebo-controlled, parallel-group phase III studies assessed the efficacy and safety of adjunctive perampanel in patients with Parkinson's disease and motor fluctuations. Methods: In both phase III studies (301 and 302), levodopa-treated patients were randomized and treated with once-daily oral placebo (n = 504), perampanel 2 mg (n = 509), or perampanel 4 mg (n = 501). The primary end point was change in daily "off" time from baseline. The treatment period was 30 weeks in study 301 and 20 weeks in study 302. Results: For any efficacy end point, perampanel 2 or 4 mg was not superior to placebo. Perampanel was well tolerated up to 4 mg/day. Conclusions: Perampanel failed to significantly improve motor symptoms versus placebo. There was also no effect on the duration or disability of levodopa-induced dyskinesia.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pérampanel</s0>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Perampanel</s0>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Perampanel</s0>
<s2>FR</s2>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Récepteur AMPA</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>AMPA receptor</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Receptor AMPA</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Fluctuation</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Fluctuations</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Fluctuación</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Sécurité</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Safety</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Seguridad</s0>
<s5>12</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Récepteur glutamate</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Glutamate receptor</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Receptor glutámato</s0>
<s5>42</s5>
</fC07>
<fN21><s1>086</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A33 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 002A33 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:12-0113807
   |texte=   Perampanel, an AMPA Antagonist, Found to Have No Benefit in Reducing "Off" Time in Parkinson's Disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Perampanel, an AMPA Antagonist, Found to Have No Benefit in Reducing "Off" Time in Parkinson's Disease

Perampanel, an AMPA Antagonist, Found to Have No Benefit in Reducing "Off" Time in Parkinson's Disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri